Nucala’s SC formulation will be favored over Cinqair’s IV method of administration.
By Astrid Kurniawan, Analyst
12 May 2016
I am an analyst for the market access and strategy team at Datamonitor Healthcare, where my aim is to provide an analysi...
Read full bio
Cinqair’s (Teva; reslizumab) IV formulation puts the drug at a disadvantageous contracting position as its first-to-market IL-5 competitor Nucala (mepolizumab; GlaxoSmithKline) is approved both for SC and IV use. US and EU payers and key opinion leaders interviewed by Datamonitor Healthcare reported preference for asthma biologics that can be administered via SC injection. IV drugs require added administrative fees, additional personnel resources, and need to be administered in an infusion center or a hospital. With SC administration, patients would still need to come to the physician office, but this process is simpler and less time-consuming. Further, there is little to no incentive, both on the provider and physician side, to administer an IV drug if an equally effective SC formulation is available. Given that Cinqair has the added cumbersome IV formulation, the drug is expected to be somewhat disadvantaged compared to Nucala. Teva is working on an SC formulation for Cinqair, but the product is still early in its development. Datamonitor Healthcare therefore expects that Nucala will continue to hold a strong position until a third IL-5 or an SC formulation of Cinqair enter the market.
“Infusions are not something that pulmonologists are typically doing, so they are likely going to have to find a rheumatologist or gastroenterologist colleague maybe that could do the infusions…They do have to set up systems in place to do the infusion. So, it is a little more complicated than a subcutaneous.” US payer Get your free demo today – simply fill out the form to the right.